Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601992 | 1.00 | HDAC1 (0.35) | HDAC1HDAC2KDM4EMEN1MAPT | |
| SCHEMBL3604577 | 0.87 | RXRA (0.38) | HDAC1HDAC2KDM4EMEN1MAPT | |
| SCHEMBL3604572 | 0.87 | RXRA (0.38) | HDAC1HDAC2KDM4EMEN1MAPT | |
| SCHEMBL3603051 | 0.85 | KDM4E (0.39) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3646386 | 0.84 | MAPT (0.36) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3646383 | 0.84 | MAPT (0.36) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL2316048 | 0.84 | ESR1 (0.42) | HDAC1HDAC2HDAC3ESR1ESR2 | |
| SCHEMBL2316040 | 0.84 | ESR1 (0.42) | HDAC1HDAC2HDAC3ESR1ESR2 | |
| SCHEMBL3607030 | 0.83 | KDM4E (0.33) | KDM4EMEN1MAPTKMT2AATM | |
| SCHEMBL3607025 | 0.83 | KDM4E (0.33) | KDM4EMEN1MAPTKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | XDH, URB2, ALOX12 | HDAC1 3817/4885HDAC2 4112/4885KDM4E 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.